Annalisa D'avola

Charterhouse Square
London, ENG EC1M6BQ, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.

Journal: The Journal of clinical investigation

Published: February 15, 2024

Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers.

Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers.

Journal: OncoTargets and therapy

Published: March 04, 2023

Advances in Understanding of Metabolism of B-Cell Lymphoma: Implications for Therapy.

Advances in Understanding of Metabolism of B-Cell Lymphoma: Implications for Therapy.

Journal: Cancers

Published: October 14, 2022

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.

Journal: Blood advances

Published: November 23, 2021

B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities.

B-cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities.

Journal: HemaSphere

Published: September 07, 2021

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.

Journal: The Journal of clinical investigation

Published: July 26, 2021

Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells.

Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 19, 2021

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.

Journal: Blood

Published: August 19, 2020

Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.

Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 25, 2018

IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.

IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.

Journal: Leukemia

Published: July 07, 2016

Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL.

Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL.

Journal: Blood

Published: March 28, 2016

Showing 1-11 of 11

Last Updated: 09/26/2026